1414 - PD-L1 testing for access to Pembrolizumab for the treatment of locally advanced or metastatic NSCLC

Page last updated: 27 March 2017

Application Detail



Description of Medical Service

TImmunoHistoChemistry (IHC) test for evaluation of Programmed Cell Death 1 Ligand (PD-L1) expression to determine eligibility for treatment with Pembrolizumab.

Description of Medical Condition

Locally advanced or metastatic NSCLC (Stage IIIb/IV).

Reason for Application

New MBS item

Medical Service Type

Co-dependent technology

Previous Application Number

Not Applicable

Associated Documentation

Application Form

PICO Confirmation

Final Protocol (PDF 2875 KB)
Final Protocol (Word 922 KB)

Assessment Report


Public Summary Document

Public Summary Document (PDF 408 KB)
Public Summary Document (Word 132 KB)

Meetings for this Application


13 August 2016


6 - 7 October 2016


24 - 25 November 2016